GAINESVILLE, Ga.–(BUSINESS WIRE)–As of July 2023, Gainesville Eye Associates and North Georgia Eye Clinic, the two largest, premier comprehensive ophthalmology practices in North Georgia, have joined together to form North Georgia Eye Associates. Tog…
Author: Business Wire
Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Regenerative Medicine Clinical Candidate CTR-107 (Noregen™) for Retinal Diseases
ROCHESTER, Mich.–(BUSINESS WIRE)–Caeregen Therapeutics Receives $1.4 M Phase 2 SBIR Grant to Advance Development of Regenerative Medicine Clinical Candidate for Retinal Diseases
Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that i…
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data for its approved and investigational medicines will be highlighted in 30 abstracts at the 2023 Association …
Novaliq 宣布 CyclASol 0.1%（环孢霉素眼用溶液）第二个关键 3 期试验数据已在《JAMA 眼科学》上发表
德国海德堡市和美国麻省剑桥市–(BUSINESS WIRE)–(美国商业资讯)–Novaliq 是一家生物制药公司，专注于基于独特的 EyeSol® 无水技术的一流和最佳眼科治疗方案。该公司今天宣布 CyclASol® 的第二个关键 3 期试验结果，即 ESSENCE-2 已经在美国医学会杂志《JAMA 眼科学》上发表。 CyclASol® 用于治疗干眼病的症状和体征，目前正在接受监管审查。美国食品和药品管理局（FDA）已经确定了处方药用户费用法案（PDUFA）行动日期，时间为 2023 年 …
Novaliq annonce la publication dans le JAMA Ophthalmology des résultats de la deuxième étude pivot de Phase 3 sur le CyclASol 0,1 % (solution ophtalmique de cyclosporine)
HEIDELBERG, Allemagne et CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Novaliq, société biopharmaceutique spécialisée dans les traitements oculaires de première qualité basés sur la technologie unique EyeSol® sans eau, a annoncé aujourd’hui que les résult…
Novaliq gibt die Veröffentlichung von Daten der zweiten Phase-3-Studie zu CyclASol 0,1 % (Cyclosporin-Augenlösung) in JAMA Ophthalmology bekannt
HEIDELBERG, Deutschland, und CAMBRIDGE, Massachusetts, USA–(BUSINESS WIRE)–Novaliq, ein biopharmazeutisches Unternehmen mit Schwerpunkt auf First- und Best-in-Class-Augentherapeutika, die auf der einzigartigen wasserfreien EyeSol®-Technologie aufbaue…
Novaliq kondigt publicatie aan van tweede cruciale Fase 3-onderzoeksgegevens over CyclASol 0,1% (cyclosporine oftalmische oplossing) in JAMA Ophthalmology
HEIDELBERG, Duitsland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novaliq, een biofarmaceutisch bedrijf dat zich richt op eersteklas en best-in-class oculaire therapieën op basis van de unieke watervrije EyeSol®-technologie, heeft vandaag aangekondigd dat de …
Novaliq annuncia la pubblicazione di dati sul secondo studio pivot di fase 3 su CyclASol 0,1% (soluzione oftalmica di ciclosporina) su JAMA Ophthalmology
HEIDELBERG, Germania & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novaliq, azienda biofarmaceutica specializzata nelle terapie oculari first in class e best in class basate sull’esclusiva tecnologia anidra EyeSol®, oggi annuncia la pubblicazione dei risultati …
Warby Parker Publishes 2022 Impact Report
NEW YORK–(BUSINESS WIRE)–Highlights impact and milestones, including distribution of more than 13 million pairs of glasses globally through its Buy a Pair, Give a Pair program
Novaliq anuncia la publicación de los datos del segundo ensayo fundamental de fase 3 sobre CyclASol 0,1 % (solución oftálmica de ciclosporina) en JAMA Ophthalmology
HEIDELBERG, Alemania & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novaliq, una empresa biofarmacéutica especializada en tratamientos oculares pioneros en su género y basados en la exclusiva tecnología EyeSol® sin agua, ha anunciado hoy que los resultados del s…
Nova Eye Medical Announces U.S. Market Clearance of the iTrack™ Advance Canaloplasty Device
FREMONT, Calif.–(BUSINESS WIRE)–Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces that it has been granted U.S. Foo…
Novaliq Announces Publication of Second Pivotal Phase 3 Trial Data on CyclASol 0.1% (Cyclosporine Ophthalmic Solution) in JAMA Ophthalmology
HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)–NOVALIQ ANNOUNCES PUBLICATION OF SECOND PIVOTAL PHASE 3 TRIAL DATA ON CYCLASOL 0.1% (CYCLOSPORINE OPHTHALMIC SOLUTION) IN JAMA OPHTHALMOLOGY
Visus Therapeutics Appoints Ophthalmology Industry Expert Jehan Tamboowalla to Senior Vice President of Business Development and Marketing
SEATTLE & IRVINE, Calif.–(BUSINESS WIRE)–Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, today announced Jehan Tamboowalla joined the …
Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as exe…
Blue Point Acquires eyebobs, Setting Its Sights on Expanded Eyewear Platform
CLEVELAND–(BUSINESS WIRE)–Blue Point Capital Partners is pleased to announce the acquisition of eyebobs, a market leader in premium reading glasses. The investment is part of the firm’s broader plan to build a unique eyewear platform designed for B2B…
Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first…
Global Blepharoplasty Market to 2028: Rising Incidence of Eye-related Disorders Drives Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Blepharoplasty Market Size, Share, Growth Analysis, By Procedure Type, By End-user – Industry Forecast 2022-2028” report has been added to ResearchAndMarkets.com’s offering. The Global Blepharoplasty Market was valu…
Pete Brown Joins Sonrava Health as Senior Vice President of Supply Chain Management
DALLAS–(BUSINESS WIRE)–Peter “Pete” Brown has joined Sonrava Health as Senior Vice President of Supply Chain Management, effective April 10. Sonrava Health is a national family of health and wellness companies – including differentiated dental office…
Ray Therapeutics to Present at Upcoming Scientific Conferences
SAN FRANCISCO–(BUSINESS WIRE)–Ray Therapeutics to Present at Upcoming Scientific Conferences